Table 2.

Patients who experienced disease progression or initiation of therapy.

No	Sex	Age at FL diagnosis	Involved GI tract	Stage	Events	Time to events (years)	Outcome	Follow-up period (years)
1	M	62	Duodenum, jejunum, rectum	I	Perigastric LN swelling	0.9	Alive with lymphoma after treatment	10.2
					Initiation of rituximab monotherapy	1.1
2	M	70	Duodenum	I	Mesenteric LN swelling	1.2	Alive with lymphoma	9.5
3	M	64	Duodenum	I	Initiation of rituximab and bendamustine therapy	2.0	Alive, NED with treatment	5.8
4	F	41	Duodenum, stomach, rectum	I	Inguinal LN swelling	2.0	Alive, NED with treatment	22.8
					Initiation of rituximab monotherapy	3.5
5	F	40	Duodenum	I	Initiation of rituximab monotherapy	2.7	Alive, NED with treatment	12.5
6	M	57	Jejunum	I	Multiple intraabdominal LN swelling	3.1	Alive with lymphoma	10.6
7	F	60	Duodenum	I	Mesenteric LN swelling	5.4	Alive, NED with treatment	8.7
					Initiation of radiotherapy	5.8
8	F	75	Duodenum	I	Cervical and mesenteric LN swelling	7.1	Alive, NED with treatment	8.9
					Initiation of obinutuzumab and bendamustine therapy	7.5

FL follicular lymphoma; GI gastrointestinal tract; LN lymph nodes; NED no evidence of disease.